Efgartigimod alfa

• Description :

  Efgartigimod alfa (ARGX-113) is a neonatal Fc receptor (FcRn) blocker. Efgartigimod alfa is an anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod alfa can be used for the research of myasthenia gravis[1].

• Product Name Alternative :

  ARGX-113

• UNSPSC :

  12352203

• Target :

  Fc Receptor (FcR)

• Related Pathways :

  Immunology/Inflammation

• Field of Research :

  Inflammation/Immunology

• Purity :

  99.50

• Solubility :

  10 mM in DMSO

• Smiles :

  [Efgartigimodalfa]

• Molecular Weight :

  (51.28 kDa)

• References & Citations :

  [1]Heo YA. Efgartigimod: First Approval. Drugs. 2022 Feb;82 (3) :341-348.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Launched

• CAS Number :

  [1821402-21-4]